The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy

Completed

• Conditions: Pre-Eclampsia; Cathepsin B Level; Pentraxin 3 Level
• Interventions: Other: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women

• Registration Number: NCT05924061
• Lead Sponsor: Sanliurfa Mehmet Akif Inan Education and Research Hospital

Brief Summary

In this study, the investigator aim was to compare Cathepsin B and Pentraxin 3 levels measured from maternal serum of pregnant women diagnosed with preeclampsia in the second trimester, the effects of these levels on maternal/ fetal outcomes and the composite results of Cathepsin B and Pentraxin 3 levels alone or together and contribute to the literature in this area.

Detailed Description

This prospective case-control study was conducted between 1 January 2022 and 31 December 2022 at Bursa Yuksek Ihtisas Training and Research Hospital. The study was conducted with pregnant women between ages of 18-45 who were diagnosed with preeclampsia in the second trimester. This study was conducted with total 156 pregnant women. participants were grouped according to the presence of preeclampsia; Group1: Patients diagnosed with preeclampsia between 20-28 weeks (study group) (n:78) , Group 2: Healthy pregnant women between 20-28 weeks without a diagnosis of preeclampsia ( control group) (n:78) . As soon as preeclampsia is diagnosed and before any treatment was started, maternal serum samples were collected in the Cathepsin B and Pentraxin 3 kit in amounts suitable for the study. The samples obtained were kept in biochemistry laboratory at -80 degrees until the study was conducted. After all samples were collected, Cathepsin B and Pentraxin 3 values were measured by ELISA method.

Study Timeline

• Study Start: 2022-01-01
• Primary Completion: 2022-12-31
• Study Completion: 2022-12-31
• Study First Submitted: 2023-04-04
• Status Verified: 2023-06
• Study First Submitted QC: 2023-06-19
• Last Update Submitted: 2023-06-19
• Study First Posted: 2023-06-29
• Last Update Posted: 2023-06-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 156

Inclusion Criteria

• Singleton pregnancy
• Pregnant women diagnosed with preeclampsia between 20-28 weeks of gestation
• Healthy pregnant women between 20-28 weeks of gestation who want to be involved in the study.

Exclusion Criteria

• Multiple pregnancies
• Pregnant women who gave birth below 24 weeks of gestation
• Pregnant women diagnosed with other hypertensive diseases of pregnancy other than preeclampsia ( gestational hypertension, chronic hypertension, superimposed hypertension)
• Pregnant women with chromosomal or congenital anomalies in the fetus
• Women with a known infective or autoimmune disease before pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Pregnant women with preeclampsia between 20-28 weeks (study group)	Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women	Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks pregnant women with preeclampsia
Healthy pregnant women between 20-28 weeks ( control group)	Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women	Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks healthy pregnant women ( control group)

Primary Outcome Measures

Name	Time	Method
Comparison of the effects and composite results of cathepsin b and pentraxin 3 levels in pregnant women diagnosed with preeclampsia	12 months	serum cathepsin b (nmoL pNA/mL) and serum pentraxin 3 (ng/ml) levels composite results on pregnant women diagnosed with preeclampsia

Trial Locations

Locations (1)

Nefise Nazlı YENIGUL; 🇹🇷 Bursa, Turkey